Latest filings (excl ownership)
15-12G
Securities registration termination
30 Nov 23
EFFECT
Notice of effectiveness
27 Nov 23
EFFECT
Notice of effectiveness
27 Nov 23
10-Q
2023 Q3
Quarterly report
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
POS AM
Prospectus update (post-effective amendment)
20 Nov 23
POS AM
Prospectus update (post-effective amendment)
20 Nov 23
8-K
Completion of Acquisition or Disposition of Assets
20 Nov 23
25-NSE
Exchange delisting
20 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
425
Business combination disclosure
8 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
8 Nov 23
DEFA14A
Additional proxy soliciting materials
2 Nov 23
425
Business combination disclosure
2 Nov 23
8-K
Entry into a Material Definitive Agreement
2 Nov 23
DEFA14A
Additional proxy soliciting materials
30 Oct 23
DEFM14A
Proxy related to merger
10 Oct 23
425
Business combination disclosure
31 Aug 23
8-K
Voting and Support Agreement
31 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
14 Aug 23
8-K
Entry into a Material Definitive Agreement
26 Jun 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
22 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate Update
15 May 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 May 23
8-K
Acer Therapeutics Announces OLPRUVAâ„¢ Commercial Launch Progressing Ahead of Schedule
1 May 23
424B2
Prospectus for primary offering
27 Apr 23
Latest ownership filings
4
STEVE ASELAGE
20 Nov 23
4
JOHN MICHAEL DUNN
20 Nov 23
4
Donald Joseph
20 Nov 23
4
Chris Schelling
20 Nov 23
4
HARRY S PALMIN
20 Nov 23
4
Jefferson E Davis
20 Nov 23
SC 13D/A
TVM Life Science Ventures VI LP
30 Mar 23
4
Adrian W Quartel
16 Mar 23
4
Bernard H Paul
16 Mar 23
4
HARRY S PALMIN
16 Mar 23
4
John Michael Klopp
16 Mar 23
4
Donald Joseph
16 Mar 23
4
Tanya Hayden
16 Mar 23
4
MICHELLE RENEE GRIFFIN
16 Mar 23
4
JOHN MICHAEL DUNN
16 Mar 23
4
Jefferson E Davis
16 Mar 23
4
STEVE ASELAGE
16 Mar 23
4
Jason Amello
16 Mar 23
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 23
SC 13D/A
Schelling Chris
2 Dec 22
4
Chris Schelling
1 Dec 22
4
STEVE ASELAGE
1 Dec 22
4
Tanya Hayden
22 Jun 22
3
Tanya Hayden
22 Jun 22
4
Adrian W Quartel
23 Feb 22
3
Adrian W Quartel
23 Feb 22
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 22
4
Bernard H Paul
21 Jan 22
3
Bernard H Paul
21 Jan 22
4
Matthew Seibt
19 Jan 22
4
Chris Schelling
19 Jan 22
4
HARRY S PALMIN
19 Jan 22
4
John Michael Klopp
19 Jan 22
4
Donald Joseph
19 Jan 22
4
MICHELLE RENEE GRIFFIN
19 Jan 22
4
JOHN MICHAEL DUNN
19 Jan 22
4
Jefferson E Davis
19 Jan 22
4
STEVE ASELAGE
19 Jan 22
4
Jason Amello
19 Jan 22
4
STEVE ASELAGE
13 Dec 21